Open-label, Randomized, 3-way Cross-over, Placebo Controlled, Single Dose Clinical Pharmacology Study in COPD Patients After Inhalation of CHF 5993 pMDI Using the Standard Actuator With or Without AeroChamber Plus Flow-Vu VHC Spacer
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2015
Price : $35 *
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Acronyms TRIPLE 4
- Sponsors Chiesi Farmaceutici
- 31 Aug 2018 Biomarkers information updated
- 18 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Feb 2015 Planned End Date changed from 1 Nov 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.